{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:18:21Z","timestamp":1793863101205,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Nature Science Foundation of China grant","award":["NSFC81801189"],"award-info":[{"award-number":["NSFC81801189"]}]},{"name":"the \"Dengfeng Project\" for the construction of high-level hospitals in Guangdong Province\u2013the First Affiliated Hospital of Shantou University Medical College Supporting Funding","award":["202003-7"],"award-info":[{"award-number":["202003-7"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin within 48\u00a0h of acute minor strokes and transient ischemic attacks (TIAs) has been indicated to effectively reduce the rate of recurrent strokes. However, the efficacy of clopidogrel has been shown to be affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. Patients carrying loss-of-function alleles (LoFAs) at a low risk of recurrence (ESRS\u2009&lt;\u20093) cannot benefit from clopidogrel plus aspirin at all and may have an increased bleeding risk. In order to optimize antiplatelet therapy for these patients and avoid the waste of medical resources, it is important to identify the subgroups that genuinely benefit from DAPT with clopidogrel plus aspirin through CYP2C19 genotyping. This study sought to assess the cost-effectiveness of CYP2C19 genotyping to guide drug therapy for acute minor strokes or high-risk TIAs in China. A decision tree and Markov model were constructed to evaluate the cost-effectiveness of CYP2C19 genotyping. We used a healthcare payer perspective, and the primary outcomes included quality-adjusted life years (QALYs), costs and the incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed to evaluate the robustness of the results. CYP2C19 genotyping resulted in a lifetime gain of 0.031 QALYs at an additional cost of CNY 420.13 (US$ 59.85), yielding an ICER of CNY 13,552.74 (US$ 1930.59) per QALY gained. Probabilistic sensitivity analysis showed that genetic testing was more cost-effective in 95.7% of the simulations at the willingness-to-pay threshold of CNY 72,100 (GDP per capita, US$ 10,300) per QALY. Therefore, CYP2C19 genotyping to guide antiplatelet therapy for acute minor strokes and high-risk TIAs is highly cost-effective in China.<\/jats:p>","DOI":"10.1038\/s41598-021-86824-9","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T06:03:08Z","timestamp":1617256988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack"],"prefix":"10.1038","volume":"11","author":[{"given":"Zeling","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuomin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"86824_CR1","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/s0140-6736(13)61097-1","volume":"381","author":"G Yang","year":"2013","unstructured":"Yang, G. et al. Rapid health transition in China, 1990\u20132010: findings from the Global Burden of Disease Study 2010. Lancet (London, England) 381, 1987\u20132015. https:\/\/doi.org\/10.1016\/s0140-6736(13)61097-1 (2013).","journal-title":"Lancet (London, England)"},{"key":"86824_CR2","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1161\/strokeaha.112.665141","volume":"43","author":"SB Coutts","year":"2012","unstructured":"Coutts, S. B. et al. What causes disability after transient ischemic attack and minor stroke?: Results from the CT and MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study. Stroke 43, 3018\u20133022. https:\/\/doi.org\/10.1161\/strokeaha.112.665141 (2012).","journal-title":"Stroke"},{"key":"86824_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/bmj.37991.635266.44","volume":"328","author":"AJ Coull","year":"2004","unstructured":"Coull, A. J., Lovett, J. K. & Rothwell, P. M. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328, 326. https:\/\/doi.org\/10.1136\/bmj.37991.635266.44 (2004).","journal-title":"BMJ"},{"key":"86824_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston, S. C. et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N. Engl. J. Med. 379, 215\u2013225. https:\/\/doi.org\/10.1056\/NEJMoa1800410 (2018).","journal-title":"N. Engl. J. Med."},{"key":"86824_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.25259\/sni_83_2020","volume":"11","author":"BWY Lo","year":"2020","unstructured":"Lo, B. W. Y., Miyawaki, S., Fukuda, H. & Koyanagi, M. Review of Toyoda K, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischemic stroke in Japan. Lancet Neurol. 2019 Jun;18(6):539\u2013548. Surg. Neurol. Int. 11, 53. https:\/\/doi.org\/10.25259\/sni_83_2020 (2020).","journal-title":"Surg. Neurol. Int."},{"key":"86824_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","volume":"129","author":"PJ Sharis","year":"1998","unstructured":"Sharis, P. J., Cannon, C. P. & Loscalzo, J. The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. 129, 394\u2013405. https:\/\/doi.org\/10.7326\/0003-4819-129-5-199809010-00009 (1998).","journal-title":"Ann. Intern. Med."},{"key":"86824_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","volume":"11","author":"LH Cavallari","year":"2018","unstructured":"Cavallari, L. H. et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc. Interv. 11, 181\u2013191. https:\/\/doi.org\/10.1016\/j.jcin.2017.07.022 (2018).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86824_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjcard.2018.05.043","volume":"122","author":"RS Barlas","year":"2018","unstructured":"Barlas, R. S. et al. Effect of antiplatelet therapy (aspirin + dipyridamole versus clopidogrel) on mortality outcome in ischemic stroke. Am. J. Cardiol. 122, 1085\u20131090. https:\/\/doi.org\/10.1016\/j.amjcard.2018.05.043 (2018).","journal-title":"Am. J. Cardiol."},{"key":"86824_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1042\/cs20090154","volume":"118","author":"A Yilmaz","year":"2009","unstructured":"Yilmaz, A. et al. Transient decrease in circulating dendritic cell precursors after acute stroke: potential recruitment into the brain. Clin. Sci. (Lond.) 118, 147\u2013157. https:\/\/doi.org\/10.1042\/cs20090154 (2009).","journal-title":"Clin. Sci. (Lond.)"},{"key":"86824_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2125.2011.03949.x","volume":"72","author":"TK Ma","year":"2011","unstructured":"Ma, T. K., Lam, Y. Y., Tan, V. P. & Yan, B. P. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. Br. J. Clin. Pharmacol. 72, 697\u2013706. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03949.x (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"86824_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1089\/gtmb.2019.0216","volume":"24","author":"EM Zelenskaya","year":"2020","unstructured":"Zelenskaya, E. M. et al. The frequency of the minor polymorphisms in the CYP2C19, VEGFR-2 genes, and clinical outcomes in russian and buryat patients with acute coronary syndrome. Genet. Test. Mol. Biomarkers 24, 338\u2013342. https:\/\/doi.org\/10.1089\/gtmb.2019.0216 (2020).","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"86824_CR12","doi-asserted-by":"publisher","first-page":"d4588","DOI":"10.1136\/bmj.d4588","volume":"343","author":"T Bauer","year":"2011","unstructured":"Bauer, T. et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343, d4588. https:\/\/doi.org\/10.1136\/bmj.d4588 (2011).","journal-title":"BMJ"},{"key":"86824_CR13","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","volume":"108","author":"JS Hulot","year":"2006","unstructured":"Hulot, J. S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244\u20132247. https:\/\/doi.org\/10.1182\/blood-2006-04-013052 (2006).","journal-title":"Blood"},{"key":"86824_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/circulationaha.116.024913","volume":"135","author":"Y Pan","year":"2017","unstructured":"Pan, Y. et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 135, 21\u201333. https:\/\/doi.org\/10.1161\/circulationaha.116.024913 (2017).","journal-title":"Circulation"},{"key":"86824_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","volume":"56","author":"JS Hulot","year":"2010","unstructured":"Hulot, J. S. et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56, 134\u2013143. https:\/\/doi.org\/10.1016\/j.jacc.2009.12.071 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86824_CR16","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/j.1538-7836.2010.03921.x","volume":"8","author":"D Sibbing","year":"2010","unstructured":"Sibbing, D. et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8, 1685\u20131693. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03921.x (2010).","journal-title":"J. Thromb. Haemost."},{"key":"86824_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.2011.132","volume":"90","author":"SA Scott","year":"2011","unstructured":"Scott, S. A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450\u20132C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328\u2013332. https:\/\/doi.org\/10.1038\/clpt.2011.132 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"86824_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.25535","volume":"86","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. Ann. Neurol. 86, 419\u2013426. https:\/\/doi.org\/10.1002\/ana.25535 (2019).","journal-title":"Ann. Neurol."},{"key":"86824_CR19","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/strokeaha.119.027465","volume":"51","author":"B Cucchiara","year":"2020","unstructured":"Cucchiara, B. et al. Disability after minor stroke and transient ischemic attack in the POINT trial. Stroke 51, 792\u2013799. https:\/\/doi.org\/10.1161\/strokeaha.119.027465 (2020).","journal-title":"Stroke"},{"key":"86824_CR20","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/strokeaha.113.000823","volume":"44","author":"DM Jia","year":"2013","unstructured":"Jia, D. M. et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 44, 1717\u20131719. https:\/\/doi.org\/10.1161\/strokeaha.113.000823 (2013).","journal-title":"Stroke"},{"key":"86824_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/jnnp.2008.143875","volume":"79","author":"PH Halkes","year":"2008","unstructured":"Halkes, P. H. et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: A meta-analysis by risk. J. Neurol. Neurosurg. Psychiatry 79, 1218\u20131223. https:\/\/doi.org\/10.1136\/jnnp.2008.143875 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"86824_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1592\/phco.28.10.1233","volume":"28","author":"JP Vande Griend","year":"2008","unstructured":"Vande Griend, J. P. & Saseen, J. J. Combination antiplatelet agents for secondary prevention of ischemic stroke. Pharmacotherapy 28, 1233\u20131242. https:\/\/doi.org\/10.1592\/phco.28.10.1233 (2008).","journal-title":"Pharmacotherapy"},{"key":"86824_CR23","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1111\/j.1582-4934.2010.01163.x","volume":"14","author":"HC Diener","year":"2010","unstructured":"Diener, H. C., Weimar, C. & Weber, R. Antiplatelet therapy in secondary stroke prevention\u2013state of the art. J. Cell. Mol. Med. 14, 2552\u20132560. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01163.x (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"86824_CR24","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","volume":"365","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ 365, l2211. https:\/\/doi.org\/10.1136\/bmj.l2211 (2019).","journal-title":"BMJ"},{"key":"86824_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/01616412.2019.1709140","volume":"42","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Qin, W. & Hu, W. An analysis of the risk of perioperative ischemic stroke in patients undergoing non-cardiovascular and non-neurological surgeries. Neurol. Res. 42, 55\u201361. https:\/\/doi.org\/10.1080\/01616412.2019.1709140 (2020).","journal-title":"Neurol. Res."},{"key":"86824_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1161\/strokeaha.109.571463","volume":"41","author":"JW Wei","year":"2010","unstructured":"Wei, J. W. et al. Secondary prevention of ischemic stroke in urban China. Stroke 41, 967\u2013974. https:\/\/doi.org\/10.1161\/strokeaha.109.571463 (2010).","journal-title":"Stroke"},{"key":"86824_CR27","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1161\/strokeaha.107.513390","volume":"39","author":"B Wettermark","year":"2008","unstructured":"Wettermark, B., Persson, A. & von Euler, M. Secondary prevention in a large stroke population: a study of patients\u2019 purchase of recommended drugs. Stroke 39, 2880\u20132885. https:\/\/doi.org\/10.1161\/strokeaha.107.513390 (2008).","journal-title":"Stroke"},{"key":"86824_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.annemergmed.2012.04.020","volume":"61","author":"DM Boudreau","year":"2013","unstructured":"Boudreau, D. M., Guzauskas, G., Villa, K. F., Fagan, S. C. & Veenstra, D. L. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann. Emerg. Med. 61, 46\u201355. https:\/\/doi.org\/10.1016\/j.annemergmed.2012.04.020 (2013).","journal-title":"Ann. Emerg. Med."},{"key":"86824_CR29","doi-asserted-by":"publisher","first-page":"104588","DOI":"10.1016\/j.oraloncology.2020.104588","volume":"103","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 103, 104588. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104588 (2020).","journal-title":"Oral Oncol."},{"key":"86824_CR30","unstructured":"Ministry of Health of the People's Republic of China. China Statistics Yearbook. Available at: https:\/\/data.cnki.net\/ValueSearch\/."},{"key":"86824_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 316, 70\u201378. https:\/\/doi.org\/10.1001\/jama.2016.8662 (2016).","journal-title":"JAMA"},{"key":"86824_CR32","doi-asserted-by":"publisher","first-page":"e000912","DOI":"10.1161\/jaha.114.000912","volume":"3","author":"Y Pan","year":"2014","unstructured":"Pan, Y. et al. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. J. Am. Heart Assoc. 3, e000912. https:\/\/doi.org\/10.1161\/jaha.114.000912 (2014).","journal-title":"J. Am. Heart Assoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86824-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T01:04:08Z","timestamp":1670029448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86824"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86824-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"1 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7383"}}